Treatment of essential thrombocythemia with anagrelide.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 7658287.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET.
Medical subject headings
- Platelet Aggregation Inhibitors
- Quinazolines
- Thrombocythemia, Essential